Yahoo Search Búsqueda en la Web

  1. Se muestran resultados de

    Thomas Breuer
    Buscar sólo Thomas Breuster

Resultado de búsqueda

  1. Leading the GSK Global Health organisation, a team of more than 200 outstanding people …. · Experiencia: GSK · Educación: INSEAD · Ubicación: Tres Cantos · Más de 500 contactos en LinkedIn. Ver el...

  2. Thomas Brewster –conocido como Tom Brewster– (Saint Andrews, 10 de abril de 1974) es un deportista británico que compite por Escocia en curling. [1] Participó en los Juegos Olímpicos de Sochi 2014, obteniendo una medalla de plata en la prueba masculina. [1]

  3. 28 de jun. de 2023 · Thomas Breuer, head of global health at GSK, agreed. His team runs the largest R&D programme aimed at tackling infectious diseases in the developing world “but in the end we are not an NGO. We...

  4. 3 de oct. de 2018 · thomas.breuer@gsk.com. We are writing to respond to The BMJ ’s feature article about the Pandemrix vaccine.” 1 Our response focuses on some of the statements in the article as well the methodology on which the major premise of the article is based. The statement by The BMJ that the available safety data were not disclosed to the ...

  5. Thomas Breuer, MD, MSc. Senior Vice President Head of Global Vaccines Development GSK Biologicals. Vaccines business characteristics. Few global players and high barriers to entry. Complex manufacturing. Large scale investment. Long product life cycles. – Complex intellectual property. High probability of R&D success. – 70% post-POC.

  6. 6 de may. de 2024 · Thomas Brewster - Thomas Fox-Brewster. Forbes Staff | Cybersecurity. I'm a senior writer for Forbes, covering security, surveillance and privacy. I'm also the editor of The Wiretap...

  7. 3 de jul. de 2014 · Jan 27. As we begin the new year, here is the fourth of four #BigIdeas2023 that could help the world move closer to ending the epidemics of #HIV, #tuberculosis, #malaria and other threats such as diarrheal diseases. 👇. linkedin.com. Thomas Breuer, MD, MSc on LinkedIn: #bigideas2023.